Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma

Video

The professor of medicine and pediatrics at Washington University in St. Louis discussed updated survival data from SPEARHEAD-1.

"SPEARHEAD is one of the most interesting things I've had the privilege of working on in my career for synovial sarcoma patients that are not only HLA*02, but also express the MAGE-A4 antigen. The ability to take patients’ T-cells out of their body, remanufacture them and put them back, has led to a T spear therapy for synovial sarcoma that has deep and durable responses. In fact, it's just been made public that they're now going for a traditional approval and no longer an accelerated approval, because the data is that strong.”

Patients with advanced synovial sarcoma treated with afamitresgene autoleucel (afami-cel; AdaptImmune) T-cell receptor SPEAR T-cell therapy in the phase 2 SPEARHEAD-1 trial (NCT04044768) have continued to experience a survival benefit. Updated survival data from the trial were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois, by Brian Van Tine, MD, PhD, professor, medicine and pediatrics, Washington University in St. Louis.

CGTLive™’s sister site, OncLive™, spoke with Van Tine to learn more about the updated data survival data, which continues to demonstrate a durable and deep response in treated patients. He noted that AdaptImmune is no longer pursuing an accelerated approval for afami-cel in favor of a traditional approval. He also touched on the manageable safety profile of afami-cel, which includes transient cases of cytokine release syndrome but no new, long-term safety signals. He shared possible next steps for the platform, including targeted other antigens besides MAGE-A4.

Click here for more coverage of ASCO 2023.

REFERENCE
Van Tine BA, Ganjoo KN, Blay JY, et al. The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma. Presented at: ASCO 2023 Annual Meeting; June 2-6; Chicago, Illinois. Poster #497
Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.